|Bid||0.00 x 1200|
|Ask||0.00 x 3000|
|Day's range||53.10 - 54.41|
|52-week range||33.36 - 55.70|
|Beta (5Y monthly)||0.67|
|PE ratio (TTM)||15.50|
|Earnings date||31 Jan 2022 - 04 Feb 2022|
|Forward dividend & yield||1.56 (2.87%)|
|Ex-dividend date||04 Nov 2021|
|1y target est||N/A|
Some Americans could prefer Moderna's booster because of perceptions that it offers higher efficacy.
Shares of pharma giant Merck (NYSE: MRK) fell by 14.9% during the month of November, according to data from S&P Global Market Intelligence. Although the drugmaker did take a hit from a clinical setback for its once-weekly oral treatment, MK-8507, for HIV-1 infection last month, the main reason Merck's stock slumped in November is the evolving situation surrounding its oral coronavirus pill molnupiravir. In brief, this COVID-19 pill, which is being jointly developed with privately held Ridgeback Biotherapeutics, exhibited a significant drop in efficacy following the final analysis of the full data set, compared to a prior interim data readout.
Omicron happened this week. So as the medical world shifts to a yet-to-be-determined degree, a question comes to mind: Who will pay for all this? In fact, who’s paid for all the COVID fighting to date?